

REMARKS UNDER 37 CFR § 1.111

Formal Matters

Claims 1-39 are pending after entry of the amendments set forth herein.

Claims 20-25, 37 and 39 are amended to remove the multiple dependency. These amendments are made only for the purpose of reducing the filing fee by reducing the total number of claims for which a fee is due, and are not intended to acquiesce or abandon any subject matter encompassed by the original claims.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

No new matter has been added.

Conclusion

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number CHOR-001.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

January 16, 2002

By:

Carol L. Francis

Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Enclosure

F:\DOCUMENT\Chor\001\Preliminary Amendment 12-19-01.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claims 20-25, 37 and 39 as follows.

20. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16] wherein the OMV and MV preparations are administered together with pharmaceutically acceptable excipients.

21. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16,] wherein the excipients comprise an adjuvant.

22. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16,] wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, alum or MF59.

23. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16,] wherein administering is by injection.

24. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16] wherein administering is oral or by aerosol administration.

25. (Amended) The method of claim 1, [methods of claims 1, 9, 14 or 16,] wherein the mammal is a human.

37. (Amended) The composition of claim 34[, 35, or 36], wherein the composition comprises at least two isolated *Neisseria meningitidis* antigens.

39. (Amended) A method for eliciting broad spectrum protective immunity against a disease caused by a *Neisseria meningitidis* species, said method comprising administering to a mammal the composition of claim 34[, 35, 36, or 38].